{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "David", "organization": "", "rank": 1, "lastname": "BARBOZA"}], "original": "By DAVID BARBOZA"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Chinese government's harsh legal crackdown on misconduct by GlaxoSmithKline, which included fraud and bribery, reflects country's increasingly assertive approach to multinational companies on its soil; case of Peter Humphrey, who was arrested in China while working as corporate investigator for pharmaceutical company, cited (Series: China Rules).", "multimedia": [{"type": "image", "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbWide.jpg", "legacy": {"wide": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-articleLarge.jpg", "legacy": {"xlarge": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "479"}, "width": 600, "subtype": "xlarge", "height": 479}, {"type": "image", "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "China Rules", "content_kicker": "China Rules", "print_headline": "China Tightens Its Grip, and Glaxo Pays a Price", "main": "Drug Giant Faced a Reckoning as China Took Aim at Bribery"}, "print_page": "1", "keywords": [{"value": "China", "is_major": "Y", "rank": "1", "name": "glocations"}, {"value": "Series", "is_major": "Y", "rank": "12", "name": "subject"}, {"value": "GlaxoSmithKline PLC", "is_major": "Y", "rank": "2", "name": "organizations"}, {"value": "Bribery and Kickbacks", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Frauds and Swindling", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Whistle-Blowers", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Fines (Penalties)", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Humphrey, Peter", "is_major": "Y", "rank": "7", "name": "persons"}, {"value": "Reilly, Mark", "is_major": "N", "rank": "8", "name": "persons"}, {"value": "Shi, Vivian", "is_major": "N", "rank": "9", "name": "persons"}, {"value": "ChinaWhys", "is_major": "N", "rank": "10", "name": "organizations"}], "snippet": "China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties....", "source": "The New York Times", "lead_paragraph": "China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties.", "word_count": "3473", "pub_date": "2016-11-01T22:59:47Z", "subsection_name": "International Business", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/11/02/business/international/china-rules-glaxo-bribes-sex-tape-whistleblower-cautionary-tale.html", "_id": "58191e6d7c459f606398d030"}